INSIGHTS
-
Rising Measles Cases in the United States
A Dangerous Resurgence Measles, once declared eliminated in the United States in 2000, has roared back in 2025 with a vengeance. The Centers for Disease Control and Prevention (CDC) reports 1,681 confirmed cases this year, a staggering increase from 285 in 2024. This marks the highest annual total since the early 1990s. The virus has
-
Fresenius Kabi Issues Voluntary Nationwide Recall of Three Lots of Famotidine Injection
Fresenius Kabi has issued a voluntary nationwide recall of three lots of Famotidine Injection USP, 20 mg per 2 mL (10 mg/mL), after laboratory testing identified an out‑of‑specification impurity result in a single lot. The recall is precautionary and intended to protect patients and maintain supply-chain integrity while further investigations continue.1 Summary of the recall
-
Erectile Dysfunction Treatment options 2025 – 2026
Quick summary What is Erectile dysfunction and how is it diagnosed ED is the persistent inability to obtain or maintain an erection adequate for sexual activity. Common causes: Typical diagnostic steps: Prescription drug Erectile dysFUNCTION treATMENT options All four are PDE5 inhibitors: they amplify the natural nitric-oxide → cGMP pathway that relaxes penile smooth muscle
-
Breakthrough Cancer Drug With No Detectable Side Effects
A significant nanomedicine breakthrough from Northwestern University, led by Prof. Chad A. Mirkin and documented in the peer-reviewed journal ACS Nano, details the transformation of the chemotherapy agent 5-fluorouracil (5-Fu) into a spherical nucleic acid (SNA) structure. According to both the article and surrounding scientific coverage, this innovation reports unprecedented increases in cancer cell targeting
-
Why More Americans Are Ditching Traditional Health Care for New Models in 2026
A Healthcare Revolution in Motion Across the United States, the way people find and experience health care is changing dramatically. Long gone are the days when nearly everyone relied on the familiar duo of a family doctor’s office and hospital networks, with insurance cards always at the ready. In their place, innovative – and sometimes
-
FDA Recall: Over 480K bottles of Teva’s Prazosin Hydrochloride
Teva Pharmaceuticals USA initiated a voluntary, nationwide recall of multiple lots of Prazosin Hydrochloride capsules after laboratory testing found levels of an N‑nitroso impurity (designated N‑nitroso Prazosin impurity C) above the FDA’s acceptable intake limit calculated using the Carcinogenic Potency Categorization Approach (CPCA). The agency classified the recall as Class II, indicating that use of
-
Managing Chemotherapy Side Effects with Clinical and Lifestyle Interventions
Best Practices for Managing Chemotherapy Side Effects Chemotherapy remains a cornerstone of modern oncology, offering improved survival and the possibility of cure for many types of cancer. Yet for most patients, chemotherapy is synonymous with a daunting array of side effects – nausea, fatigue, mucositis, neuropathy, immunosuppression, and others – that can compromise quality of
-
Digital Health Platforms, Wearables, and AI-Powered Apps: Advancing the Personalized Diagnosis and Management of Hormonal Imbalance in Women
Hormonal imbalances represent one of the most prevalent and complex health challenges faced by women across their lifespan, with implications ranging from reproductive health, metabolic function, and emotional well-being to the onset of chronic conditions such as polycystic ovary syndrome (PCOS), thyroid disorders, and osteoporosis. Traditionally, the diagnosis and management of hormonal disorders in women
-
Changes to Medicare Drug Plans for 2026
The landscape of Medicare prescription drug coverage is poised for considerable transformation in 2026, bringing a blend of policy-driven reforms, technical updates, and new beneficiary protections. These changes, shaped largely by ongoing implementation of the Inflation Reduction Act (IRA) of 2022, affect every facet of Medicare Part D – including out-of-pocket costs, coverage scope, accessibility,
-
FDA Recalls 141,984 Bottles of Atorvastatin Calcium After Failed Dissolution Testing
On 10 October 2025 the U.S. Food and Drug Administration (FDA) classified a nationwide recall of Atorvastatin Calcium tablets, initiated by Ascend Laboratories, LLC, as a Class II recall because multiple lots “failed dissolution specifications,” affecting 141,984 bottles distributed across the United States. The recalled product is a generic formulation of atorvastatin (a statin widely